公开(公告)号：US11833146B2

公开(公告)日：2023-12-05

申请号：US16607402

申请日：2018-05-30

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mai Miyamoto ,  Sadaharu Kotani

IPC: A61K31/4745 ,  A61P25/28 ,  A61K31/445

CPC classification number: A61K31/4745 ,  A61K31/445 ,  A61P25/28

Abstract: There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1):




or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II):





or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11147803B2

公开(公告)日：2021-10-19

申请号：US16607459

申请日：2018-05-30

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mai Miyamoto ,  Sadaharu Kotani

IPC: A61K31/4745 ,  A61K31/4375 ,  A61P25/28 ,  A61K31/13

Abstract: There is provided a therapeutic agent for Alzheimer's disease for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (I): or a pharmaceutically acceptable salt thereof, and memantine represented by formula (II): or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220378706A1

公开(公告)日：2022-12-01

申请号：US17831863

申请日：2022-06-03

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Edgar Schuck ,  Robert Lai ,  Ishani Savant Landry ,  Bhaskar Rege ,  Mai Miyamoto ,  Sadaharu Kotani ,  Kanta Horie

IPC: A61K9/20 ,  A61P25/28 ,  A61K9/16 ,  A61K9/48 ,  A61K31/437

Abstract: The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 inhibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quin olin-4(5H)-one or pharmaceutically acceptable salts thereof.

公开(公告)号：US11484502B2

公开(公告)日：2022-11-01

申请号：US16609514

申请日：2018-05-30

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Edgar Schuck ,  Robert Lai ,  Ishani Savant Landry ,  Bhaskar Rege ,  Mai Miyamoto ,  Sadaharu Kotani ,  Kanta Horie

IPC: A61K9/20 ,  A61P25/28 ,  A61K9/16 ,  A61K9/48 ,  A61K31/437

Abstract: The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 inhibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quin olin-4(5H)-one or pharmaceutically acceptable salts thereof.

公开(公告)号：US11179387B2

公开(公告)日：2021-11-23

申请号：US16607402

申请日：2018-05-30

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mai Miyamoto ,  Sadaharu Kotani

IPC: A61K31/4745 ,  A61P25/28 ,  A61K31/445

Abstract: There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1): or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II): or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200078306A1

公开(公告)日：2020-03-12

申请号：US16609514

申请日：2018-05-30

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Edgar Schuck ,  Robert Lai ,  Ishani Savant Landry ,  Bhaskar Rege ,  Mai Miyamoto ,  Sadaharu Kotani ,  Kanta Horie

IPC: A61K9/20 ,  A61K31/437 ,  A61P25/28 ,  A61K9/48 ,  A61K9/16

Abstract: The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 inhibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quin olin-4(5H)-one or pharmaceutically acceptable salts thereof.